Navigation Links
GenVec Reports Fourth Quarter and 2011 Year-End Financial Results
Date:3/15/2012

GAITHERSBURG, Md., March 15, 2012 /PRNewswire/ -- Today GenVec, Inc. (NASDAQ: GNVC) announced financial results for the fourth quarter and year ended December 31, 2011.  For the year ended December 31, 2011, the Company reported a net loss of $7.4 million, or $0.58 per share, compared with a net loss of $12.3 million, or $0.97 per share, for the year ended December 31, 2010. GenVec ended the year with $26.4 million in cash, cash equivalents, and short-term investments.  

"In 2011 we made significant progress in our hearing loss program, partnered with Novartis, and advanced the development of our attractive portfolio of vaccine opportunities. We also enhanced our differentiated, proprietary core technology, adding further value to our product pipeline. We believe 2012 has the potential for important advances in these programs," stated Paul H. Fischer, Ph.D., GenVec's President and CEO.

2011 and Recent Corporate Highlights

  • We extended our Research Collaboration and License Agreement with Novartis (NYSE: NVS).  Under the extension, Novartis will fund research at GenVec through January 2013 to support its hearing loss and balance disorders program.
  • We achieved the second milestone in our research collaboration with Novartis which was triggered by the successful completion of certain preclinical development activities.  After this achievement, we are eligible to receive up to an additional $206.0 million in milestone payments if certain clinical, regulatory, and sales milestones are met, in addition to royalties on future sales.
  • Research was published describing how GenVec technology, utilizing a vector targeted to supporting cells and limited in expression to those cells, can be used to restore balance function in an animal model.
  • We expanded our relationship with Merial, initially focused on the development of
    '/>"/>

  • SOURCE GenVec, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. GenVec President and Chief Executive Officer Announces Retirement
    2. GenVec Achieves Second Milestone in Collaboration
    3. GenVec to Present at the 2011 10th Annual BIO Investor Forum
    4. GenVec Renews Stockholder Rights Plan
    5. GenVec Reports First Quarter 2011 Financial Results
    6. GenVec Regains Compliance with NASDAQ Listing Requirements
    7. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
    8. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
    9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
    10. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
    11. GenVec Reports Third Quarter 2009 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
    (Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
    (Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
    (Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
    Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
    ... cellular biologists have made tremendous scientific advances by ... and pathways. Researchers at the University of Wisconsin-Madison ... understanding by putting the pieces back together, mathematically. ... biological engineering, developed computer models of a relatively ...
    ... ST. LOUIS, Feb. 6 Stereotaxis, Inc. (Nasdaq:, ... financial results for the,fourth quarter and full year ended ... market opens. The Company will host a conference call ... Eastern Time to discuss,the Company,s fourth quarter results and ...
    ... by $14 millionSEATTLE, Feb. 6 Cell Therapeutics, Inc. ... has engaged the services of a strategic advisory consulting ... developing strategic options for a partnership, asset divestment or ... the preclinical drug development arm of CTI, in Bresso, ...
    Cached Biology Technology:Mathematical models reveal how organisms transcend the sum of their genes 2Stereotaxis Announces Fourth Quarter and Full Year 2008 Earnings Release Date and Conference Call 2CTI Seeks Strategic Alternative for Italian Facility 2CTI Seeks Strategic Alternative for Italian Facility 3
    (Date:4/14/2014)... face the decision of whether to get a ... decision can be even more challenging. Now, a ... decisions in families of children with autism and ... parents reported the benefits of dog ownership included ... to learn responsibility. , "Children with autism spectrum ...
    (Date:4/14/2014)... plant growth chamber bound for the International Space ... resupply mission may help expand in-orbit food production ... astronauts something they don,t take for granted, fresh ... to study the in-orbit function and performance of ... and its plant "pillows." The investigation will focus ...
    (Date:4/14/2014)... sponges sound like creatures from a B-grade horror movie. ... the deep sea. Scientists first discovered that some sponges ... seven carnivorous species have been found in all of ... marine biologist Lonny Lundsten and two Canadian researchers describes ... deep seafloor, from the Pacific Northwest to Baja California. ...
    Breaking Biology News(10 mins):Dog ownership benefits families of children with autism, MU researcher finds 2Veggie will expand fresh food production on space station 2Researchers describe 4 new species of 'killer sponges' from the deep sea 2Researchers describe 4 new species of 'killer sponges' from the deep sea 3
    ... National Science Foundation (NSF), bioengineers from the University of ... to characterize the thousands of control elements critical to ... mix and match these "DNA parts" in synthetic organisms ... a single designer microbe can take years to create ...
    ... easy as plugging it into your tee shirt or jeans, ... reporting an advance in that direction with an easier way ... e-Textiles that double as a rechargeable battery. Their report ... a monthly journal. "Wearable electronics represent a developing new ...
    ... applications ranging from medical devices such as MRIs to surveillance ... of 1996, Congress directed the government to sell essentially all ... government for its investment in the helium and its storage. ... from the National Research Council, assesses whether selling off the ...
    Cached Biology News:NSF grant to launch world's first open-source genetic parts production facility 2NSF grant to launch world's first open-source genetic parts production facility 3NSF grant to launch world's first open-source genetic parts production facility 4
    Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
    Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
    ... The 2/3D Waver Shaker combines shaking and ... with a 330 x 330 mm stainless steel ... top incubator and cold room operation. The platform ... degree for a vigorous with action and rotation ...
    Anti-DNA Polymerase a, Human Description: 50 l Research Focus: cancer & cell proliferation Storage: 4C Shipping Temperature: 4C...
    Biology Products: